RhumbLine Advisers’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-89,242
| Closed | -$3.43M | – | 4413 |
|
|
2023
Q2 | $3.43M | Buy |
89,242
+7,471
| +9% | +$192K | ﹤0.01% | 1606 |
|
|
2023
Q1 | $1.89M | Buy |
81,771
+678
| +0.8% | +$16.2K | ﹤0.01% | 1836 |
|
|
2022
Q4 | $2.13M | Buy |
81,093
+4,382
| +6% | +$97.1K | ﹤0.01% | 1757 |
|
|
2022
Q3 | $1.51M | Buy |
76,711
+13,314
| +21% | +$267K | ﹤0.01% | 1929 |
|
|
2022
Q2 | $1.11M | Buy |
63,397
+13,213
| +26% | +$207K | ﹤0.01% | 2089 |
|
|
2022
Q1 | $821K | Buy |
50,184
+4,362
| +10% | +$59.3K | ﹤0.01% | 2211 |
|
|
2021
Q4 | $747K | Buy |
45,822
+4,739
| +12% | +$67.5K | ﹤0.01% | 2336 |
|
|
2021
Q3 | $524K | Buy |
41,083
+1,695
| +4% | +$22.3K | ﹤0.01% | 2521 |
|
|
2021
Q2 | $556K | Buy |
39,388
+23,340
| +145% | +$373K | ﹤0.01% | 2518 |
|
|
2021
Q1 | $249K | Sell |
16,048
-770
| -5% | -$12.6K | ﹤0.01% | 2763 |
|
|
2020
Q4 | $267K | Buy |
16,818
+1,019
| +6% | +$15.4K | ﹤0.01% | 2717 |
|
|
2020
Q3 | $192K | Sell |
15,799
-3,186
| -17% | -$42.7K | ﹤0.01% | 2703 |
|
|
2020
Q2 | $219K | Buy |
18,985
+1,790
| +10% | +$24.7K | ﹤0.01% | 2731 |
|
|
2020
Q1 | $236K | Hold |
17,195
| – | – | ﹤0.01% | 2511 |
|
|
2019
Q4 | $101K | Buy |
17,195
+17
| +0.1% | +$92 | ﹤0.01% | 2874 |
|
|
2019
Q3 | $91K | Buy |
17,178
+305
| +2% | +$2.02K | ﹤0.01% | 2902 |
|
|
2019
Q2 | $130K | Buy |
16,873
+556
| +3% | +$8.47K | ﹤0.01% | 2889 |
|
|
2019
Q1 | $325K | Sell |
16,317
-405
| -2% | -$7.06K | ﹤0.01% | 2500 |
|
|
2018
Q4 | $221K | Buy |
16,722
+5,405
| +48% | +$108K | ﹤0.01% | 2685 |
|
|
2018
Q3 | $416K | Sell |
11,317
-830
| -7% | -$26.6K | ﹤0.01% | 2352 |
|
|
2018
Q2 | $425K | Buy |
12,147
+4,165
| +52% | +$160K | ﹤0.01% | 2375 |
|
|
2018
Q1 | $371K | Buy |
7,982
+295
| +4% | +$10.8K | ﹤0.01% | 2347 |
|
|
2017
Q4 | $288K | Sell |
7,687
-1,419
| -16% | -$62K | ﹤0.01% | 2489 |
|
|
2017
Q3 | $485K | Buy |
9,106
+128
| +1% | +$7.61K | ﹤0.01% | 2318 |
|
|
2017
Q2 | $512K | Buy |
8,978
+1,082
| +14% | +$54.3K | ﹤0.01% | 2283 |
|
|
2017
Q1 | $424K | Buy |
7,896
+210
| +3% | +$11.9K | ﹤0.01% | 2325 |
|
|
2016
Q4 | $438K | Buy |
7,686
+628
| +9% | +$38K | ﹤0.01% | 2290 |
|
|
2016
Q3 | $439K | Buy |
7,058
+1,518
| +27% | +$107K | ﹤0.01% | 2277 |
|
|
2016
Q2 | $313K | Buy |
+5,540
| New | +$337K | ﹤0.01% | 2505 |
|
|
2016
Q1 | – | Sell |
-1,692
| Closed | -$238K | – | 2998 |
|
|
2015
Q4 | $238K | Buy |
+1,692
| New | +$230K | ﹤0.01% | 2703 |
|
|
2015
Q3 | – | Sell |
-1,421
| Closed | -$215K | – | 3022 |
|
|
2015
Q2 | $215K | Buy |
+1,421
| New | +$235K | ﹤0.01% | 2851 |
|
RhumbLine Advisers's KDNY Position: Q3 2023 in Review
RhumbLine Advisers sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 89,242 shares — an estimated $3.43M sold.
RhumbLine Advisers first reported a position in KDNY in Q2 2015 and held it in 31 quarters. The position peaked at $3.43M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- RhumbLine Advisers reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- RhumbLine Advisers sold 89,242 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3.43M.
- RhumbLine Advisers first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 31 quarters.
- RhumbLine Advisers's Chinook Therapeutics, Inc. Common Stock position peaked at $3.43M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.